




Please join us for a virtual presentation

Understanding, Diagnosing, and Treating Congenital Sucrase-Isomaltase Deficiency

Webcast Login Information to be provided prior to the program



KEYNOTE SPEAKER

Anne Boney, MEd, RD, LDN

Wednesday, August 12, 2020

8:30 PM ET (7:30 PM CT, 6:30 PM MT, 5:30 PM PT)

Tuesday, August 18, 2020

7:00 PM ET (6:00 PM CT, 5:00 PM MT, 4:00 PM PT)

Wednesday, September 16, 2020

6:00 PM ET (5:00 PM CT, 4:00 PM MT, 3:00 PM PT)

Thursday, September 24, 2020

6:00 PM ET (5:00 PM CT, 4:00 PM MT, 3:00 PM PT)

REGISTRATION

Advanced registration is required. To register, visit:

<http://www.pharmethodportal.com/qolmedical/register>

Please enter the Program ID:

8/12 - Program ID 10458

8/18 - Program ID 10459

9/16 - Program ID 10462

9/24 - Program ID 10461

Or contact your local QOL Medical representative

Indication

Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

- Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
- Do not use Sucraid® with patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
- Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
- Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
- Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
- The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
- DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
- Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light.
- For full Prescribing Information, please visit: https://www.sucraid.com/wp-content/uploads/2019/12/SucPI_R0219.pdf



According to the PhRMA Code on Interactions with Healthcare Professionals, attendance at this informational presentation is limited to healthcare professionals. Accordingly, attendance by guests or spouses cannot be accommodated.